Urinary Tract Infection Lower Acute
Conditions
Keywords
Sanjin tablets, efficacy and safety, recurrence rate, randomized, double blind, parallel control, multi-center clinical study
Brief summary
The purpose of this study is to evaluate the efficacy, safety and immune mechanism of Sanjin tablets for the treatment of acute simple lower urinary tract infection and its influence on recurrence rate.
Detailed description
In order to evaluating the efficacy, safety and immune mechanism of Sanjin tablets for the treatment of acute simple lower urinary tract infection and its influence on recurrence rate and through research data to guide clinical, improving the rational use of drugs, especially the rational application of antibiotics. In this study, a randomized, double blind, parallel control of positive drugs, multi-center clinical study will be established. According to the relevant regulations of the CFDA, 252 cases need to be registered at least. These cases will be divided into treatment group（Sanjin tablets+ levofloxacin simulants），control group 1（Sanjin tablets simulants +levofloxacin）and control group 2（Sanjin tablets+ levofloxacin）. Each group will be treated for 7 days and followed up for 2 times. The efficacy indicators of this study were mainly from three dimensions: syndrome, laboratory routine examination and bacteriology examination. The symptom scores and cytokine changes of each group before and after treatment were observed.
Interventions
DRUGSanjin tablets
Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin simulants,0.1g, po bid, for 7 days.
DRUGSanjin tablets simulants
levofloxacin ,0.1g, po bid, for 7 days+Sanjin tablets simulants,3 pills /time, 4 times/ day, for 7 days.
DRUGLevofloxacin
Sanjin tablets,3 pills /time, 4 times/ day, for 7 days+levofloxacin,0.1g, po bid, for 7 days.
Sponsors
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Shanghai University of Traditional Chinese Medicine
Guangdong Provincial Hospital of Traditional Chinese Medicine
Hubei Hospital of Traditional Chinese Medicine
Chengdu University of Traditional Chinese Medicine
Yunnan Provinical Hospital of Traditional Chinese Medicine
China Academy of Chinese Medical Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 50 Years
Healthy volunteers
No
Inclusion criteria
1. Subjects aged 18 to 50 years of age. 2. Meets the western diagnostic criteria of acute simple lower urinary tract infection, the disease duration does not exceed 72 hours. 3. Urine retention in the screening period -1-0 days, bacterial culture results were sensitive to levofloxacin.(Urine retention for bacterial culture and clinical treatment at the same time) 4. The syndrome differentiation of TCM is syndrome of dampness-heat in lower jiao. 5. Did not receive antibiotic treatment within 48 hours Before being selected. 6. The inclusion of those who confirmed not pregnant 7. Those who agree to participate in this clinical trial and sign the informed consent, the process of informed consent meet the relevant provisions of the GCP.
Exclusion criteria
1. Those who are allergic to the test drug ingredients or quinolones. 2. In the past, there was a history of bacterial culture that was not sensitive to levofloxacin. 3. Diagnosed as complicated urinary tract infection. 4. Patients with urinary calculi or obstruction, urinary tuberculosis, renal papillary necrosis, perinephric abscess or neurogenic bladder. 5. Combined with vaginitis symptoms, genital ulcers or gonorrhea. 6. Combined with severe cardiopulmonary disease, liver and kidney disease, advanced tumor, blood, central nervous system (such as the history of epilepsy) or other serious or progressive disease. 7. A patient who has a neurological or mental illness and cannot cooperate. 8. Infected persons who must use other antibacterial drugs in combination. 9. Pregnancy, lactating women or recent birth planners. 10. Those who have participated in other clinical trials within 3 months before being selected.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The lower urinary tract infection symptoms of 252 participants will be assessed | After 7 days of medication | The symptoms mainly includes frequent urination,urgent urination,urinary pain, lower abdominal pain and pain in the kidney area.If these symptoms disappear after 7 days of medication,it indicates the subject is cured. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| The urine leukocyte of 252 participants will be assessed | After 7 days of medication | If the urine leukocyte return to normal value after 7 days of medication,it indicates the subject is cured. |
| The bacteriological examination of 252 participants | After 7 days of medication | If the original infected part of the specimen did not regenerate the original infected pathogen after 7 days of medication,it indicates the subject is cured. |
| The recurrence rate of subjects who is cured in 252 participants will be assessed by lower urinary tract infection symptoms | 28 days after the end of treatment | If the lower urinary tract infection symptoms of subjects who is cured appears again in the fourth week after end of medication,it indicates the subject has relapsed. |
| The recurrence rate of subjects who is cured in 252 participants will be assessed by urine leukocyte | 28 days after the end of treatment | If the urine leukocyte value of subjects who is cured rises again in the fourth week after end of medication,it indicates the subject has relapsed. |
| The recurrence rate of subjects who is cured in 252 participants will be assessed by bacteriological examination | 28 days after the end of treatment | If the urine culture of subjects who is cured indicates that the original urinary tract pathogen is positive again in the fourth week after end of medication,it indicates the subject has relapsed. |
Contacts
Primary ContactYanming Xie, BA
Backup ContactLianxin Wang, Doctor
Outcome results
None listed